GT Biopharma, Inc.

Biotechnology • Healthcare • San Francisco, CA, United States • GTBP (NCM)

GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550 that targets B7-H3 on the surface of advanced solid tumors; and GTB-7550, a product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.

415 919 4040 315 Montgomery Street, San Francisco, CA 94104, United States

Stock Performance (90 Days)

Data through Dec 26, 2025

Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

GT Biopharma Stock Logs Best Session In Over 9 Months On Promising Cancer Trial Data; Retail Eyes Double-Digit Rally - Stocktwits

Stocktwits • Oct 8

GT Biopharma stock rises as Phase 1 trial advances to higher dose - Investing.com

Investing.com • Nov 19

EXCLUSIVE: GT Biopharma Reports Progresses Phase 1 Trial Of Lead Drug Candidate For Blood Cancers - Yahoo Finance

Yahoo Finance • Oct 8

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

GlobeNewswire • Nov 14

Risk Report: Why GT Biopharma Inc OXIA stock is a strong analyst pick - Watch List & Advanced Swing Trade Entry Alerts - moha.gov.vn

moha.gov.vn • Dec 22

Other Biotechnology Companies

Vertex Pharmaceuticals Inc. / MA

$118.68B market cap

Regeneron Pharmaceuticals, Inc.

$82.72B market cap

Alnylam Pharmaceuticals, Inc.

Frequently Asked Questions

Has GT Biopharma, Inc. had layoffs?

No layoff events have been recorded for GT Biopharma, Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.

How many employees does GT Biopharma, Inc. have?

GT Biopharma, Inc. has approximately 1 employees.

What industry is GT Biopharma, Inc. in?

GT Biopharma, Inc. operates in the Biotechnology industry, within the Healthcare sector.

Is GT Biopharma, Inc. a publicly traded company?

Yes, GT Biopharma, Inc. is publicly traded under the ticker symbol GTBP on the NCM. The company has a market capitalization of approximately $0.01 billion.

Where is GT Biopharma, Inc. headquartered?

GT Biopharma, Inc. is headquartered in San Francisco, CA, United States at 315 Montgomery Street, San Francisco, CA 94104, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.